Albert Font Pous

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida et al. · Nature Medicine · 2019 · 571 citations · Full text

Medicine, Oncology, Urology +13

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Bernadett Szabados, Mark Kockx, Zoe J. Assaf et al. · European Urology · 2022 · 190 citations · Full text

Medicine, Oncology, Urology +13

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

Thomas Powles, Alejo Rodríguez‐Vida, Ignacio Durán et al. · Journal of Clinical Oncology · 2018 · 90 citations

Medicine, Pharmacology, Surgery +14

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

Bernadett Szabados, Alejo Rodríguez‐Vida, Ignacio Durán et al. · European Urology Oncology · 2021 · 28 citations

Medicine, Oncology, Surgery +14

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

Joaquim Bellmunt Molins, Jesús García-Donás Jiménez, Begoña P. Valderrama et al. · Clinical Genitourinary Cancer · 2020 · 14 citations

Medicine, Oncology, Pharmacotherapy +7